Adalimumab (Humira®) dosing frequency in RA patient assistance programs

被引：0
|
作者：
McAndrews, MB [1 ]
Kosch, K [1 ]
Kern, C [1 ]
Holly, K [1 ]
Haas, JN [1 ]
机构：
[1] Abbott Labs, Publ Hlth Policy & Strategy, Abbott Pk, IL 60064 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2004年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：265 / 266
页数：2
相关论文
共 50 条
  • [1] IMPACT OF PATIENT SUPPORT PROGRAMS (PSP) OF ADALIMUMAB (HUMIRA®) ON BIOLOGICS ADHERENCE IN PATIENTS TREATED WITH ADALIMUMAB (HUMIRA®) IN ARGENTINA
    Luissi, Aurelia
    Gonzalez, Rosanna
    Pardal, Dario
    Cosentino, Vanesa
    Dantur, Gabriela
    Kanevsky, Diego
    Castillo, Leandro
    Roberto Soriano, Enrique
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S82 - S82
  • [2] The clinical and radiographic efficacy of every-other-week vs. weekly dosing frequency of adalimumab (HUMIRA®) in the treatment of early rheumatoid arthritis (RA).
    van Vollenhoven, R
    Breedveld, FC
    Kavanaugh, AF
    Cohen, SB
    Perez, JL
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S134 - S134
  • [3] Workplace impacts of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA)
    Birnbaum, Howard
    Pike, Crystal
    Kaufman, Rebecca
    Schiller, Matthew
    Shi, Lizheng
    Sun, Peter
    Ray, Saurabh
    Cifaldi, Mary
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S459 - S459
  • [4] The cost effectiveness of adalimumab (HUMIRA®) in patients with RA:: A Finnish analysis
    Bansback, NJ
    Brennan, A
    Sengupta, N
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 513 - 514
  • [5] The cost effectiveness of adalimumab (HUMIRA®) in UK patients with moderate to severe RA
    Bansback, NJ
    Brennan, A
    Sengupta, N
    Pang, F
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 512 - 513
  • [6] Impact of adalimumab (HUMIRA®) on patient-reported outcomes
    Loftus, E. V.
    Feagan, B. G.
    Colombel, J. F.
    Wu, E. Q.
    Yu, A.
    Pollack, P. F.
    Chao, J.
    Mulani, P.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S456 - S456
  • [7] The cost-utility of adalimumab (Humira) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Pang, F.
    Winding, B.
    VALUE IN HEALTH, 2006, 9 (06) : A223 - A223
  • [8] THE EFFECT OF DISEASE DURATION ON CLINICAL OUTCOMES FOLLOWING ADALIMUMAB (HUMIRA®) THERAPY IN RA
    Emery, P.
    Fleischmann, R.
    Strand, V.
    Reiss, W. G.
    Spencer-Green, G.
    Segurado, O. G.
    RHEUMATOLOGY, 2004, 43 : 38 - 39
  • [9] The cost-effectiveness of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Winding, B.
    Cifaldi, M.
    Pang, F.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 15 - 15
  • [10] Subgroup analysis of radiographic progression in RA patients with moderate disease treated with adalimumab (Humira®)
    Keystone, EC
    Furst, DE
    Kavanaugh, AF
    Spencer-Green, GT
    Szczerbak, NA
    Mydler, TT
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 267 - 267
12345